Article
Author(s):
Tampere, Finland-Both the M2 Single Use microkeratome and the M2 microkeratome with the new 90-?m head (Moria, Antony, France) have been performing well in clinical trials.
Researchers offer insights into wet AMD: Study reveals potential to enhance anti-VEGF therapy with experimental drug to preserve vision
Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD
Formosa Pharmaceuticals announces top-line results from Chinese trial evaluating APP13007
Innovation Series: Expanding access to eye care, advice for aspiring innovators from DMEI ophthalmology residents (part 3)
LumiThera’s Valeda Light Delivery System receives marketing authorization from FDA
Study: Aromatherapy decreased postoperative patient anxiety and pain associated with oculoplastic surgery